Crossmark

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study

Published Online: 2023-05-18

Published Print: 2023-08

Authors

Kivitz, Alan https://orcid.org/0000-0002-1045-1310
Wells, Alvin F. https://orcid.org/0000-0001-7311-7689
Vargas, Juan I. https://orcid.org/0000-0002-7674-3850
Baraf, Herbert S. B.

Rischmueller, Maureen https://orcid.org/0000-0001-5057-3286
Klaff, Justin

Khan, Nasser

Li, Yihan

Carter, Kyle

Friedman, Alan

Durez, Patrick
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02049138 at ClinicalTrials.gov

Documents that mention this clinical trial

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
https://doi.org/10.1007/s40744-023-00557-x

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
https://doi.org/10.1136/rmdopen-2021-002110
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2023-05-18

Version of Record valid from 2023-05-18
More Information

Article History

Received: 4 January 2023

Accepted: 25 April 2023

First Online: 18 May 2023

Document is current